Document is current
Any future updates will be listed below
-
Authors
Kwee, Anastasia K. A. L. https://orcid.org/0000-0002-9056-1885
Luijk, Bart
de Jong, Pim A.
Groen, Harry J. M.
Aerts, Joachim G. J. V.
Charbonnier, Jean-Paul
Vliegenthart, Rozemarijn
Mohamed Hoesein, Firdaus A. A.
- License Information
-
More Information
Article History
Received: 13 June 2023
Revised: 24 August 2023
Accepted: 14 September 2023
First Online: 11 November 2023
Declarations
:
: The scientific guarantor of this publication is Prof. P. A. de Jong.
: The authors of this manuscript declare relationships with the following companies: P. d. J. reports grants from Philips Healthcare. H. G. reports consulting fees from Eli Lilly and Novartis. J. P. C. is an employee and shareholder of Thirona. R. V. reports grants from the Dutch Cancer Foundation, Dutch Organization for Scientific Reports, Siemens Healthineers, and Bayer.Other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: Written informed consent was available from all subjects in this study.
: This study was approved by the Dutch and Belgian Ministry of Health and by the ethical review board of the University Medical Center Utrecht (approval number 03/40).
: No study subjects or cohorts have been previously reported.
: • Retrospective• Cross-sectional study• Multicenter study
